Open Beta
TREN
MetriLume
TREN

US marketsSPRY

SEC-sourced researchBeta

SPRY

ARS Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001671858
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 89,149,000.0000 USD; December 2025: 84,278,000.0000 USD89.1M USD0 USD0December 2024December 2025
SPRY · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202489,149,000.0000Mar 9, 2026
December 202584,278,000.0000Mar 9, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202584,278,000.0000-171,298,000.0000-170,866,000.0000327,652,000.0000213,394,000.0000Mar 9, 2026
December 202489,149,000.00007,998,000.000013,548,000.0000351,153,000.000094,355,000.0000Mar 9, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$84.28MDecember 2025Mar 9, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$89.15MDecember 2024Mar 9, 202610-K
Net incomeNetIncomeLoss-$171.3MDecember 2025Mar 9, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$170.87MDecember 2025Mar 9, 202610-K
Total assetsAssets$327.65MDecember 2025Mar 9, 202610-K
Total liabilitiesLiabilities$213.39MDecember 2025Mar 9, 202610-K

New filings

Explore methodology ↗